gmp
gmp

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Theratechnologies

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              NCRI Cancer Conference

              Participation Not Confirmed

              Update your events

              Theratechnologies Confirms Issuance of U.S. Patent Covering the Use of Tesamorelin in the Treatment of Individuals Suffering From NAFLD/NASH

              Contact the Supplier

              Lead Product(s): Egrifta

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: F8

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 13, 2020

              Details:

              The company is also plan on filing patent applications in other jurisdictions to expand our protection of tesamorelin.

              Bausch Health

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              CANADA Canada

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              NCRI Cancer Conference

              Participation Not Confirmed

              Update your events

              Bausch Health Announces Favorable Topline Results From Investigative Formulation of Rifaximin SSD IR

              Contact the Supplier

              Lead Product(s): Rifaximin,Lactulose

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 31, 2020

              Details:

              In the study, the treatment arm evaluating 40 mg BID of rifaximin SSD IR plus standard of care therapy met its primary endpoint of time to resolution of OHE.

              PharmaCompass__DigitalAd